As the coronavirus (SARS-CoV-2) continues to wreak havoc throughout the world, scientists have been working diligently to come up with a solution to this daunting pandemic. Hopes remain high for a vaccine, but a safe and effective one may not come soon enough to prevent more people from being infected.
In the meantime, researchers are looking furiously for alternative forms of treatment that can help those who have already been infected. We know so far that steroids and a new antiviral medication called Remdesivir can provide some relief by acting directly on the virus and preventing replication, but better medications are needed, and soon.
We can also find solutions by learning how the immune system protects us against viral infections. Novel biomedical solutions involve B cells: Convalescent plasma therapy and monoclonal antibodies. By mimicking the immune system’s operation, biomedical researchers are making significant progress toward this end, highlighting the elegant and sophisticated design of the immune system.
When a virus or another microorganism enters the body, it is initially captured by sentinel cells in our immune system. These cells break the microorganism into many fragments and “present” these fragments to special cells called B cells. The B cells that “recognize” the fragments will be recruited in the fight against the microorganism. The cells will replicate themselves in high numbers and become factories that produce proteins called antibodies whose goal is to neutralize the microorganism and protect the body from further harm. The population of B cells is a clone of the original one that recognized the fragments presented by the sentinel cells and the antibodies are highly specific in targeting the particular infecting microorganism.
Convalescent Plasma Therapy
When a person is in the recovery stage from a viral infection, these B cells produce a significant amount of specific antibodies against the virus circulating in their blood. This principle is the basis for convalescent plasma therapy, in which the blood from a person who has recovered from a viral infection is harvested and the plasma or liquid portion of the blood that contains these antibodies is separated. This plasma is then transfused to a sick person with the hope that it contains enough antibodies to fight the virus and let the person recover more rapidly.
Even though the principles for convalescent plasma therapy are straightforward, the plasma may not have enough neutralizing antibodies to help the sick person who is receiving it. If this is the case, the benefit may be minimal. One of the solutions for this problem is to “pool” many donors and prepare a mixture of plasma from different donors in the hope that one may have enough neutralizing antibodies to fight the infection. Another solution is to screen the plasma for those neutralizing antibodies and use the plasma units that have a high number of antibodies against a pathogen.
In a second research effort, scientists have sought to take the guesswork out of the process of harvesting convalescent plasma by employing a new technique in the medical field called monoclonal antibodies. Monoclonal antibodies try to mimic the way in which the B cells protect us against viral infections. These antibodies are proteins designed to attach to specific three-dimensional molecules. That interaction can result in the modification of a cell function or, in the case of infectious diseases, block a pathogen from entering a cell.
The use of monoclonal antibodies is relatively new. The first monoclonal antibody was licensed in 1986.1 Today there are over 75 FDA-licensed monoclonal antibodies that researchers use to treat cancer, chronic inflammatory diseases, cardiovascular diseases, and to aid in transplantation. However, only a handful of them are available for the treatment of infectious diseases. One of the most recent successful such applications involved treatment of Ebola virus.2
There are several ways to manufacture monoclonal antibodies, but all are complex and expensive. Some of them use human tissue and some use transgenic mice.3 Once biomedical researchers obtain the desired antibody (or mixture of antibodies), it proceeds through clinical trials to evaluate its efficacy as a treatment for a disease. The process to produce an effective monoclonal antibody is long and can take months to years. Nevertheless, this solution has materialized by studying the human immune system in exquisite detail.
The COVID-19 Challenge
Coronaviruses have a very distinct protein on their surface that resembles a crown. It is this protein (SPIKE protein) that gives the virus its name (corona = crown). The interaction of this protein with the ACE2 protein on the surface of a human cell allows the virus to invade the cell and start its replication cycle. During the first months of the pandemic, researchers studied the SPIKE protein in great depth and they have now developed monoclonal antibodies against this protein.4 As of today, a few companies have moved to the testing phase for some of these antibodies in clinical trials. However, results may not be available until late 2020. Nevertheless, some people believe that researchers will produce monoclonal antibodies before we have a vaccine against SARS-CoV-2.5
The Case for Design
The coronavirus pandemic has sparked a massive hunt for solutions that can help decrease the virus’s global impact. The amount of resources and the number of people involved in the development of novel therapies is astounding.
It is remarkable to think that with all the accumulated knowledge in the world and with a massive amount of resources behind this research, it will take us many months to accomplish what the immune system can do in just a few days. The complexity and efficiency with which our bodies run this process speak loudly about the exquisite design of our immune system. As the psalmist writes, we truly are “fearfully and wonderfully made.”
- Justin K. H. Liu, “The History of Monoclonal Antibody Development—Progress, Remaining Challenges and Future Innovations,” Annals of Medicine and Surgery 3, no. 4 (December 2014): 113–16, .
- Sabue Mulangu et al., “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” New England Journal of Medicine 381 (December 12, 2019): 2293–2303,
- Laura M. Walker and Dennis R. Burton, “Passive Immunotherapy of Viral Infections: ‘Super Antibodies’ Enter the Fray,” Nature Reviews Immunology 18 (January 30, 2018): 297–308,
- Xiaolong Tian et al., “Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-Specific Human Monoclonal Antibody,” Emerging Microbes and Infections, vol. 9 no. 1 (February 17, 2020): 382–85,
- Jon Cohen, “Antibodies May Curb Pandemic before Vaccines,” Science 369, no. 6505 (August 14, 2020): 752–53, doi:10.1126/science.369.6505.752.
THE AUTHORFrancisco Delgado
BIOFrancisco Delgado was born in Mexico. He did his premedical studies at the University of Arizona and received his medical degree with honors from Universidad La Salle in Mexico City. After comple… Read more about Francisco Delgado.
STILL CURIOUS? LEARN MORE…
Have you ever had a deep spiritual encounter? One that changed your life?
The biggest island in the United States also is the fastest growing. Thanks to a steadily rising hot plume from the lower mantle, Hawaii Island’s land area grows by an average of a little more than 40 acres per year. Though geophysicists have known about hot mantle plumes for several decades, only in the past few weeks have they gained an understanding of the source and mechanisms that produce hot plumes.
Did Earth hide some of its treasure on the Moon?
NOW THAT YOU’VE DISCOVERED REASONS TO BELIEVE
Get the latest delivered directly to you by subscribing to the RTB Weekly Digest.
About Reasons to Believe
RTB’s mission is to spread the Christian Gospel by demonstrating that sound reason and scientific research—including the very latest discoveries—consistently support, rather than erode, confidence in the truth of the Bible and faith in the personal, transcendent God revealed in both Scripture and nature. Learn More »
Support Reasons to Believe
Your support helps more people find Christ through sharing how the latest scientific discoveries affirm our faith in the God of the Bible.DONATE NOW
U.S. Mailing Address
818 S. Oak Park Rd.
Covina, CA 91724
|New International VersionEveryone who does evil hates the light, and will not come into the light for fear that their deeds will be exposed. But whoever lives by the truth comes into the light, so that it may be seen plainly that what they have done has been done in the sight of God.Read at Bible GatewayRead all of John 3|
- P (855) 732-7667
- P (626) 335-1480
- Fax (626) 852-0178
- © Reasons to Believe
Reasons to Believe is a nonprofit organization designated as tax-exempt under Section 501(c)3 by the Internal Revenue Service. Donations are tax-deductible to the full extent of the law. Our tax ID is #33-0168048. All Transactions on our Web site are safe and secure.